Search results

1462 results

Sorted by Date . Sort by Relevance

  1. The committee noted that there was no clinical evidence showing that having sodium zirconium cyclosilicate improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing sodium zirconium cyclosilicate plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: mortality disease progression patterns of RAAS inhibitor use healthcare utilisation, and health-related quality of life.

    Recommendation ID TA599/1 Question The committee noted that there was no clinical evidence showing that having sodium zirconium cyclosilicate

  2. Most women will need to use contraception for more than 30 years. Patterns of contraceptive use vary with age, ethnicity, marital status, fertility intention, education and lifestyle. Large prospective cohort studies are needed to identify: patterns of use (initiation, continuation and switching between methods) of LARC methods compared with non‑LARC methods factors that influence the patterns of use of LARC.

    Recommendation ID CG30/2 Question Most women will need to use contraception for more than 30 years. Patterns of contraceptive use vary

  3. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family therapy, psychodynamic psychotherapy and interpersonal psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate to severe depression?

    Recommendation ID NG134/3 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family

  4. What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration of follow‑up, frequency of follow‑up appointments, the type of examination or blood tests, and the roles of primary and secondary care in follow‑up?

    Recommendation ID NG131/2 Question What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who

  5. What is the most suitable surveillance protocol (including the role of digital rectal examination [DRE] and prostate-specific antigen [PSA] measures) for people for whom active surveillance is appropriate, as assessed by multiparametric MRI and biopsy, when there are no clinical concerns during follow‑up?

    Recommendation ID NG131/1 Question What is the most suitable surveillance protocol (including the role of digital rectal examination [DRE]

  6. The committee recommended that data should be collected to evaluate the system impact of adopting the lead‑I ECGs on both primary and secondary care. In particular, data should be collected on how ECGs generated by the devices would be interpreted in practice, including staff time needed to interpret the ECG traces and associated costs.

    Recommendation ID DG35/2 Question The committee recommended that data should be collected to evaluate the system impact of adopting the